TORN Oversold at SupportTORN offers non-custodial anonymous transactions on Ethereum.
Now the asset is oversold on a strong support line.
We can see a bounce from here!
Buy-signal
RAMPUSDT oversoldRAMP is the multi-chain DeFi lending platform that maximizes capital efficiency on assets.
Ramp aims to empower users with access to a global, blockchain-agnostic liquidity network. rUSD can be minted on Binance Smart Chain and Polygon, with more chains in the near future.
now is sitting oversold at a support area. looks like an interesting buy opportunity.
CWBR Upside PotentialCWBR closed 2 months ago a $15.0 Million Public Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
On the other hand, Cantor Fitzgerald brokerage has a $2.5 price target for it.
52 Week Range 0.34 - 2.27 Just bounced from its lowest support.
KMPH $50 Million Share Repurchase ProgramWhen most of the companies are diluting their shares and insiders are selling, KemPharm, Inc. (KMPH) does the opposite.
Insiders are buying and the Board of Directors authorizes a program to repurchase up to $50 million of the Company’s outstanding stock valid through December 31, 2023. It is equivalent to 18% of KemPharm’s current market capitalization.
Because of the short term puts i have 2 approaches for KMPH:
dump to 7.17 and then go to 11.45
or
bounce from the strong support which it has right now and go to $14.50
Looking forward to read your opinion about it.
Novonix ST: the upside prevails as long as 9.20 is support.Alternative scenario: the downside breakout of 9.20 would call for 7.10.
My pivot point stands at 8.20.
My preference: the upside prevails as long as 0.20 is support.
Comment:
the RSI is above its neutrality area at 50.
The MACD is positive and above its signal line.
The configuration is positive.
Moreover, the stock is trading above both its 20 and 50 day moving average (respectively at 9.11 and 9.11).
Trade Safe -
Jimster45
FTM Fantom bounced from supportFTM Fantom bounced from the strong support and it looks to aim higher.
But what is FTM?
Fantom is a fast, high-throughput open-source smart contract platform for digital assets and dApps.
Fantom’s aBFT consensus protocol delivers unparalleled speed, security, and reliability.
Enjoy almost instant transactions and extremely low fees.
Looking forward to read your opinion about it.
LINK/BTC HAS BOTTOMED! BUY NOW?I personally think LINK/BTC has bottomed and I’ll be adding some here for my spot holdings.
(SPOT trade🚨)
TP1 = $0.00104 🎯
TP2 = $0.001692 🎯
TP3 = $0.00303 🎯
Trade safe ~ BYA
FTFT New Blockchain Division | digital currency trading serviceThe blockchain division purpose is to develop, operate and manage the Company's previously announced bitcoin mining farm in the United States and Paraguay and to coordinate its announced Dubai-based digital currency trading service and crypto asset management.
My price target is the 3.15 resistance.
QNRX first FDA-approved treatment for Netherton SyndromeQuoin Pharmaceuticals (NASDAQ: QNRX ) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.
This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome.
JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. ( QNRX ) with a Market Outperform rating and a price target of 8usd.
QNRX is massively oversold having a bullish divergence chart formation and fundamentals that can skyrocket the price to 12 usd in my opinion!
Could be a Great buy opportunity at $1.91 today!
GBPCAD (LONG) SignalLong position on GBPCAD bit late to posting as price has already moved away from my entry. Bullish engulfing candle supports the initial idea.
USDCAD: $1.30 Upside TAnticipating $1.30 to deliver by Tuesday EOD.
Been a successful week since last post.
+300 points.
Happy Holidays
:)
FWBI all time lowFirst Wave BioPharma is a clinical-stage biopharmaceutical company that specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases.
52 Week Range 1.27 - 26.30
Now the price is close to all time low and looks like a buy opportunity!
CWBR antiaging stock Price Target I think antiaging stocks will be the new FAANGS in 5 to 10 years.
Immortality here, on earth, is the next frontier for the medicine.
CohBar is developing mitochondria-based therapeutics for the treatment of chronic and age-related diseases.
On 11/12/2021 Cantor Fitzgerald brokerage Initiated Coverage on CWBR with an Overweight rating and a price target of $2.50.
This all time low looks like a great buy opportunity for me.
Looking forward to read your opinion on it.
ASTR Launch for NASA from Cape Canaveral in JanuaryAstra Space, Inc. (ASTR) to deploy its first satellite in orbit for the National Aeronautics and Space Administration (NASA) in January 2022.
At this price before this big upcoming catalyst, this looks like a great buying opportunity!
My short term price target is 11.8usd.
Looking forward to read your opinion about it.
BKKT 15K calls expiring today + Dark Pool Prints More than 15K calls on BKKT are expiring today. and those are the calls from the last month only.
The strike price varies from 14 to 75usd.
The price of the stock is now 9.08usd.
Yesterday we saw a volume of 32mil.
Besides the 32mil, Dark Pool Prints were 33Mil.
Dark pools are private exchanges not accessible by the investing public. Dark pools facilitate block trading by institutional investors who did not wish to impact the markets with their large orders and obtain adverse prices for their trades.
I expect strong intraday volatility.
i know it seems a little bit exaggerated, but i wouldn`t be surprised the see BKKT trading at 14-15usd.
don`t forget that on Nov 21 BKKT was trading at $50.80.
Looking forward to see how this trading day will end!
What is your opinion about this trade?
QNRX Market Outperform Price Target !!Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd.
Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.
This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome.
My price target is the 12usd resistance.
FWBI Opportunities in Multi-Billion-Dollar Commercial MarketsJames Sapirstein
Chairman, President and CEO of First Wave BioPharma, Inc.:
"We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative proctosigmoiditis (estimated at $5 billion); Crohn’s disease (estimated at $7.4 billion); immune checkpoint inhibitor-associated colitis (estimated at $22 billion for immune checkpoint inhibitors); and exocrine pancreatic insufficiency (EPI), a dangerous digestive disorder that afflicts most patients with cystic fibrosis and chronic pancreatitis (estimated at $1.6 billion)."
Short term price target: 3.31, medium term: 6.44, end of 2022: 9.5.
NRSN High Volatility IPONeuroSense Therapeutics Ltd. (NRSN) listed yesterday only 2,000,000 shares on NASDAQ Capital at a price of $6.00.
Due to the extremely low liquidity, high volatility is expected.
I rarely see 2Mil shares float in a stock which also dropped from 6usd to 3.83usd in the pre-market right now.
I rate this a Buy!
C3 AI trend reversal Price TargetDepartment of Defense Awards C3 AI $500 Million on a new five-year Production-Other Transaction Agreement.
The stock bounced from all time low.
My price target is the $47.5 resistance.
730% upside stock according to CitigroupArdelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year.
Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap.
That`s why in the last 2 days we saw volumes higher than 100Mil.
Recently, on 11/30/2021, Yigal Nochomovitz from Citigroup Boosted the Price Target from Positive to Buy increasing the price target from $7.00 to $13.00.
The price of the stock is now 1.7usd.
My valuation is much higher!
I look forward to read your opinion about it.
CFVI Rumble to rival YouTube?Rumble platform growth from 1.6 million average monthly active users in Q3 2020 to a record 36 million average monthly active users in Q3 2021.
44 million monthly active users in August 2021.
CFVI merger transaction values Rumble at an enterprise value of $2.1 billion.
Do you see more upside from here?
BBIG Vinco Ventures Price Target by year`s endBBIGVinco Ventures stock looks to have big potential on this trend reversal.
They own aspiring TikTok competitor Lomotif.
My price target is 5.5usd by year`s end and 15usd in 2022.
Looking forward to read your opinion about it!
